Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ista up on Phase III Xibrom data

Ophthalmic company ISTA gained $0.82 (15%) to $6.33 on Monday after the

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE